Navigation Links
Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America

2008 Accomplishments Provide Continuing Springboard for Growth in 2009 and


NEW YORK, June 5 /PRNewswire-FirstCall/ -- Monsanto's international seed brands serve as an ideal launching pad that positions the company for new launches of biotechnology traits with significant scale and ramp-up speed, Brett Begemann, Monsanto's executive vice president of global commercial, will tell investors today at the Merrill Lynch Agricultural Chemicals Conference in New York.

Begemann will cite the examples of Argentina and Brazil, where the company recently received separate regulatory approvals for corn biotechnology traits. In Argentina, Monsanto received the first-ever approval for a double-stack trait combination, YieldGard Corn Borer with Roundup Ready Corn 2, and plans to offer the combination on more than 1 million acres in its year of introduction. Likewise, Monsanto received planting approval for the YieldGard Corn Borer trait in Brazil and is planning for a 1 million to 2 million acre launch for the upcoming 2008-2009 season.

"If you combine the scale of our seed businesses in Argentina and Brazil with our proven ability to deliver traits, we're in the best competitive position to enter new trait markets quickly and with an immediate financial benefit," said Begemann. "These two approvals came a year ahead of our original plan, accelerating this opportunity and giving us what we believe is a significant first-mover advantage that translates to an enduring advantage in these new markets."

Begemann's comments will be part of a broader update on the company's five-year growth plan, which targets doubling the company's 2007 gross profit by 2012. With the company's third quarter just completed, Begemann will indicate that the company's 2008 progress on its six identified growth drivers continues to set the stage for further growth in 2009 and beyond. Monsanto will report its third-quarter earnings on

SOURCE Monsanto Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
2. Halogen Customers Shape Industry-Leading Employee Performance and Talent Management Solution
3. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
6. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
7. Transgene: Cash Position of EUR 119 Million as of September 30, 2007
8. Easily Lift, Transfer and Reposition Patients with Ground-Breaking Liftaem(TM) System from Smart Medical Technology, Inc.
9. ADVENTRX Announces Consolidation of Clinical and Management Positions
10. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
11. Cephalon General Counsel John E. Osborn to Resign Position
Post Your Comments:
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... oncology company developing new treatments for cancer and ... Chief Executive Officer, will be presenting at the ... Las Vegas :Event:Aegis Capital Corporation 2015 ... PDTLocation:Brahms 2 room, The Encore @ The Wynn ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, today announced its schedule ... place in the month of October: Stem ... RepliCel will be presenting at the annual Partnering Forum, ... to be held October 7-9 in La ...
Breaking Biology Technology:
... sole U.S. supplier of 3M electrosurgical grounding pads ... ... Industries, Inc. and,3M Health Care announce an exclusive license and supply ... agreement,Medline has acquired the exclusive license and sales rights in the ...
... Eastern Time Today, GAITHERSBURG, Md., March 6 ... and corporate progress for,the full year ended December 31, ... further demonstrated that Iomai,s,vaccine and immunostimulant patches can be ... chief executive officer,of Iomai. "This lays the foundation for ...
... (Pink Sheets: VXGN), a biopharmaceutical company, today reported its,year ... a view to,ensuring that stockholders have the most current ... with Raven biotechnologies,inc. VaxGen,s Board of Directors has set ... of Stockholders to vote on the proposed merger., ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
... and Nanosystems Research (IBN), Austrian Academy of Sciences ... of Technology, Cambridge, USA report the study of ... Designer Lipid-Like Peptide Surfactants” in the May 30th ... Their findings not only help us to ...
... a chronic and progressive lung disorder from which most patients ... by the insidious onset of dyspnea or cough and usually ... coworkers present in an article published in the online, open-access ... that a subset of IPF patients has a short duration ...
... chronic lung disease typically characterized by the slow but ... patients live about five years after diagnosis. However, according ... online journal PLoS ONE, a subset of patients with ... progression to complete pulmonary failure and death without a ...
Cached Biology News: